2. Academic Validation
  3. Long-term antibody responses to the Ebola virus and the vaccine vector after rVSV-ZEBOV vaccination in DRC

Long-term antibody responses to the Ebola virus and the vaccine vector after rVSV-ZEBOV vaccination in DRC

  • Vaccine. 2025 Jul 23:62:127537. doi: 10.1016/j.vaccine.2025.127537.
Christian M Kahusu 1,  Laurène Peckeu-Abboud 2,  Odin Goovaerts 3,  Élysée Matungulu 4,  Leo Heyndrickx 5,  Kevin K Ariën 5,  Selien Oostvogels 3,  Ange Mubiala 4,  Saidou Milua 4,  Ilombe Myriam Mbilizi 4,  Samuel Shamamba 4,  Naomie Bayoka 4,  Elie Ishara-Nshombo 6,  Célestin Tshimanga 4,  Antoine Nkuba 7,  Martine Peeters 8,  Bobo Bazola 4,  Jessy Sabue 4,  Michel Ngimba 6,  Noëlla Mukanya 6,  Patrick Tshita 4,  Christian Kinzungu 4,  Dacquin M Kasumba 9,  Olivier Tshiani 10,  Placide Mbala-Kingebeni 11,  Laurens Liesenborghs 12,  Daniel Mukadi-Bamuleka 13,  Sabue Mulangu 14,  Hugo Kavunga-Membo 13,  Wim Adriaensen 3
Affiliations

Affiliations

  • 1 Clinical Immunology Department, Institut national de recherche biomédicale (INRB), Kinshasa, Congo; Clinical Immunology Unit, Department of Clinical Sciences, Institute of Tropical Medicine (ITM), Antwerp, Belgium; Virology, Antiviral Drug & Vaccine Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven (KUL), Belgium. Electronic address: christian.kahusu@inrb.cd.
  • 2 Haute Autorité de Santé (HAS), French NITAG, Paris, France.
  • 3 Clinical Immunology Unit, Department of Clinical Sciences, Institute of Tropical Medicine (ITM), Antwerp, Belgium.
  • 4 Clinical Immunology Department, Institut national de recherche biomédicale (INRB), Kinshasa, Congo.
  • 5 Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine (ITM), Antwerp, Belgium.
  • 6 Rodolphe Mérieux Institut National de Recherche Biomédicale Goma, Goma, North Kivu, Congo.
  • 7 Virology Departement, Institut national de recherche biomédicale (INRB), Kinshasa, Congo; Service of Microbiology, Department of Medical Biology, Faculty of Medicine, University of Kinshasa, Congo.
  • 8 Institut de recherche pour le développement IRD Montpellier, Montpellier, France.
  • 9 Clinical Immunology Department, Institut national de recherche biomédicale (INRB), Kinshasa, Congo; Service of Microbiology, Department of Medical Biology, Faculty of Medicine, University of Kinshasa, Congo.
  • 10 Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • 11 Epidemiology and Global Health Department, Institut national de recherche biomédicale (INRB), Kinshasa, Congo; Service of Microbiology, Department of Medical Biology, Faculty of Medicine, University of Kinshasa, Congo.
  • 12 Virology, Antiviral Drug & Vaccine Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven (KUL), Belgium; Clinical Emerging Infectious Diseases, Department of Clinical Sciences, Institute of Tropical Medicine (ITM), Antwerp, Belgium.
  • 13 Rodolphe Mérieux Institut National de Recherche Biomédicale Goma, Goma, North Kivu, Congo; Virology Departement, Institut national de recherche biomédicale (INRB), Kinshasa, Congo; Service of Microbiology, Department of Medical Biology, Faculty of Medicine, University of Kinshasa, Congo.
  • 14 Clinical Immunology Department, Institut national de recherche biomédicale (INRB), Kinshasa, Congo; Service of Microbiology, Department of Medical Biology, Faculty of Medicine, University of Kinshasa, Congo; Ridgeback Biotherapeutics, Miami, FL, USA.
PMID: 40706506 DOI: 10.1016/j.vaccine.2025.127537
Abstract

Zaïre ebolavirus (EBOV) remains a serious threat with a high case fatality rate in humans, particularly in the Democratic Republic of Congo (DRC). To cope with previous epidemics, the single-dose and prophylactic rVSV-ZEBOV vaccine was widely applied. However, evidence on the duration of protection and, consequently, the need or timing for booster doses is lacking. Therefore, we investigated in a cross-sectional study design the antibody persistence and neutralizing capacity against three strains of the Orthoebolavirus zaïrense species within healthcare workers (HCWs) who were previously vaccinated in different outbreaks across DRC. The presence of vector-directed immunity was studied via seropositivity to VSV proteins. In total, 133 HCWs were recruited and grouped according to their time from initial vaccination (1-2, 2-3, >3 years), in addition to a control group of 20 unvaccinated HCWs. In 1-2 year vaccinated participants (n = 10), an overall high antibody response (100 % seropositivity) specific to the vaccine-targeted EBOV glycoprotein (GP) of the Kikwit strain was observed, in comparison to <50 % seropositivity to the Mayinga and Kissidougou GP EBOV variants. This antibody trend persisted up to 4 years after vaccination, but overall seropositivity rates decreased to 76.8 % (Kikwit), 38.3 % (Mayinga), and 44.6 % (Kissidougou) for participants vaccinated >3 years ago. Only a minority (n = 6) among all time groups of HCWs with high antibody titers still had demonstrable neutralizing capacity. No persistent VSV-specific antibody responses were observed at any time, suggesting no to low interference with booster doses. Complementing prior findings, our results thus suggest a persistently detectable but strain-specific and slowly declining antibody response to EBOV up to 4 years after vaccination. Our data supports the administration of booster doses after 1-2 years for optimal protection, highlights potential strain-restrictive vaccine-induced immunity, and may inform on correlates of long-term protection.

Keywords

Correlates of protection; Durability; Ebola virus disease; Neutralizing antibody; Strain-specific; Vaccination.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z